Loss of E-cadherin promotes ovarian cancer metastasis via α5-integrin, which is a therapeutic target

Cancer Research

Volumn 68, Issue 7, 2008, Pages 2329-2339

  Sawada, Kenjiro ^a   Mitra, Anirban K ^a   Radjabi, A Reza ^a   Bhaskar, Vinay ^c   Kistner, Emily O ^a   Tretiakova, Maria ^a   Jagadeeswaran, Sujatha ^a   Montag, Anthony ^a   Becker, Amy ^a   Kenny, Hilary A ^a   Peter, Marcus E ^a,b   Ramakrishnan, Vanitha ^c   Yamada, S Diane ^a   Lengyel, Ernst ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c PDL BioPharma Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA5 INTEGRIN; BETA CATENIN; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; FOCAL ADHESION KINASE; IMMUNOGLOBULIN G; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN ANTIBODY; UVOMORULIN;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CELL ADHESION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; OVARY METASTASIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; UPREGULATION; XENOGRAFT;

ANIMALS; BLOTTING, WESTERN; CADHERINS; CELL ADHESION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTEGRIN ALPHA5; INTEGRIN ALPHA5BETA1; MAP KINASE SIGNALING SYSTEM; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PROGNOSIS; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL;

EID: 42049107076     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-5167     Document Type: Article

References (41)

1. Auersperg N, Wong AST, Choi K, et al. Ovarian surface epithelium: biology, endocrinology and pathology. Endocr Rev 2001;22:255-88.
2. Cannistra SA. Cancer of the ovary. N Engl J Med 2004; 351:2519-29.
3. Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 2006;17:548-58.
4. Cavallaro U, Christofori G. Cell adhesion and signalling by cadherins and IG-cams in cancer. Nat Rev 2004;4:118-32.
5. Veatch AL, Carson LF, Ramakrishnan S. Differential expression of the cell-cell adhesion molecule E-cadherin in ascites and solid human ovarian tumor cells. Int J Cancer 1994;58:393-9.
6. Darai E, Scoazec JY, Walker-Combrouze F, et al. Expression of cadherins in benign, borderline, and malignant ovarian epithelial tumors: a clinicopathologic study of 60 cases. Hum Pathol 1997;28:922-8.
7. Symowicz J, Adley BP, Gleason KJ, et al. Engagement of collagen-binding integrins promotes matrix metalloproteinase-9-dependent E-cadherin ectodomain shedding in ovarian carcinoma cells. Cancer Res 2007;67:2030-9.
8. Cannistra SA, Kansas GS, Niloff J, et al. Binding of ovarian cancer cells to peritoneal mesothelium in vitro is partly mediated by CD44H. Cancer Res 1993;53:3830-8.
9. Ahmed N, Riley C, Oliva K, et al. Ascites induces modulation of a6b1 integrin and urokinase plasminogen activator receptor expression and associated functions in ovarian carcinoma. Br J Cancer 2005;92:1475-85.
10. Sawada M, Shii J, Akedo H, et al. An experimental model for ovarian tumor invasion of cultured mesothelial cell monolayer. Lab Invest 1994;70:333-8.
11. Le Floc'h A, Jalil A, Vergnon I, et al. αE β7 integrin interaction with E-cadherin promotes antitumor CTL activity by triggering lytic granule polarization and exocytosis. J Exp Med 2007;204:559-70.
12. Sawada K, Radjabi AR, Shinomiya N, et al. C-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res 2007;67:1670-80.
13. Shell S, Park S, Radjabi AR, et al. Let-7 expression defines two differentiation stages of cancer. Proc Natl Acad Sci U S A 2007;104:11400-5.
14. Boles BK, Ritzenthaler J, Birkenmeier T, et al. Phorbol ester-induced U-937 differentiation: effects on integrin a5 gene transcription. Am J Physiol Cell Mol Physiol 2000;278:703-12.
15. Kenny HA, Krausz T, Yamada SD, et al. Development of an organotypic peritoneal three-dimensional culture to study peritoneal attachment of ovarian cancer cells. Int J Cancer 2007;121:1463-72.
16. Lengyel E, Schmalfeldt B, Konik E, et al. Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer. Gynecol Oncol 2001;82:291-8.
17. Lengyel E, Wang H, Gum R, et al. Elevated urokinase-type plasminogen activator receptor expression in a colon cancer cell line is due to a constitutively activated extracellular-signal regulated kinase 1 dependent signaling cascade. Oncogene 1997;14:2563-74.
18. Lengyel E, Prechtel D, Resau JH, et al. C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/Neu. Int J Cancer 2005;113:678-82.
19. Mell LK, Meyer JJ, Tretiakova MS, et al. Prognostic significance of E-cadherin protein expression in pathological stage I-III endometrial cancer. Clin Cancer Res 2004;10:5546-53.
20. Wingerter P, Kazman I, Norberg S, et al. Uniform overexpression and rapid accessibility of a5b1 integrin on blood vessels in tumors. Am J Pathol 2005;167:193-211.
21. Hynes R. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992;69:11-25.
22. Nhieu G, Isberg R. Bacterial internalization mediated by b1chain integrins is determined by ligand affinity and receptor density. EMBO J 1993;12:1887-95.
23. Hoschuetzky H, Aberle H, Kemler R. h-catenin mediates the interaction of the cadherin-catenin complex with epidermal growth factor receptor. J Cell Biol 1994;127:1375-80.
24. Adachi A, Taki T, Higashiyama M, et al. Significance of integrin-a5 gene expression as a prognostic factor in node-negative non small cell lung cancer. Clin Cancer Res 2000;6:96-101.
25. Yuecheng Y, Hongmei L, Xiaoyan X. Clinical evaluation of E-cadherin expression and its regulation mechanism in epithelial ovarian cancer. Clin Exp Metastasis 2006;23:65-74.
26. Makarla PB, Saboorian MH, Ashfaq R, et al. Promoter hypermethylation profile of ovarian epithelial neoplasms. Clin Cancer Res 2005;11:5365-9.
27. Shibata K, Kikkawa F, Nawa A, et al. Fibronectin secretion from human peritoneal tissue induces Mr 92,000 type IV collagenase expression and invasion in ovarian cancer cell lines. Cancer Res 1997;57:5416-20.
28. Strobel T, Cannistra SA. b1-integrins partly mediate binding of ovarian cancer cells to peritoneal mesothelium in vitro. Gynecol Oncol 1999;73:362-7.
29. Casey RC, Burleson KM, Skubitz KM, et al. b1-integrins regulate the formation and adhesion of ovarian carcinoma multicellular spheroids. Am J Pathol 2001;159:2071-80.
30. Maschler S, Wirl G, Spring H, et al. Tumor cell invasiveness correlates with changes in integrin expression and localization. Oncogene 2005;24:2032-41.
31. Munshi HG, Ghosh S, Mukhopadhyay S, et al. Proteinase suppression by E-cadherin-mediated cell-cell attachment in premalignant oral keratinocytes. J Biol Chem 2002;277:38159-67.
32. Niedbala MJ, Crickard K, Bernacki R. Interactions of human ovarian tumor cells with human mesothelial cells grown on extracellular matrix. Exp Cell Res 1985;160:499-513.
33. Heath R, Jayne D, O'Leary R, et al. Tumor-induced apoptosis in human mesothelial cells: a mechanism of peritoneal invasion by Fas Ligand/Fas interaction. Br J Cancer 2004;90:1437-42.
34. Wong AST, Gumbiner BM. Adhesion-independent mechanism for suppression of tumor cell invasion by E-cadherin. J Cell Biol 2003;161:1191-203.
35. Qian X, Karpova T, Sheppard AM, et al. E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases. EMBO J 2004;23:1739-48.
36. Kim S, Bell K, Mousa SA, et al. Regulation of angiogenesis in vivo by ligation of integrin a5b1 with the central cell-binding domain of fibronectin. Am J Pathol 2000;156:1345-62.
37. Magnussen A, Kasman I, Norberg S, et al. Rapid access of antibodies to a5b1 integrin overexpressed on the luminal surface of tumor blood vessels. Cancer Res 2005;65:2712-21.
38. Ramakrishnan V, Bhaskar V, Law DA, et al. Preclinical evaluation of an anti-a5b1 integrin antibody as a novel anti-angiogenic agent. J Exp Ther Oncol 2007;5:273-86.
39. Maglott A, Bartik P, Cosgun S, et al. The small a5b1 integrin antagonist, SJ749, reduces proliferation and clonogencity of human astrocytoma cells. Cancer Res 2006;66:6002-8.
40. Stoeltzing O, Liu W, Reinmuth N, et al. Inhibition of integrin a5b1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice. Int J Cancer 2003;104:496-503.
41. Livant DL, Brabec RK, Pienta KJ, et al. Anti-invasive, antitumorigenic, and antimetastatic activities of the PHSCN sequence in prostate carcinoma. Cancer Res 2000;60:309-20.